FDA OKs extended release liquid ADHD medication
Attention deficit hyperactivity disorders is now a common diagnosis with the Center for Disease Control and Prevention estimating that almost one in 10 children aged 4-17, has at some time, received a diagnosis of ADHD. Common treatment strategies for ADHD include cognitive-behavioral therapy and pharmaceuticals. The Food and Drug Administration has now approved Quillivant XR, the first once-daily, extended-release liquid methylphenidate available for patients with ADHD.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063